SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories is currently trading at Rs. 381.55, up by 2.70 points or 0.71% from its previous closing of Rs. 378.85 on the BSE.

The scrip opened at Rs. 380.00 and has touched a high and low of Rs. 385.00 and Rs. 373.00 respectively. So far 116508 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 578.30 on 04-Sep-2012 and a 52 week low of Rs. 357.20 on 04-Jun-2013.

Last one week high and low of the scrip stood at Rs. 385.00 and Rs. 369.00 respectively. The current market cap of the company is Rs. 16086.30 crore.

The promoters holding in the company stood at 63.52% while Institutions and Non-Institutions held 20.58% and 13.80% respectively.

India’s drug regulator has ordered inspection of the two manufacturing facilities of Ranbaxy Laboratories that were banned from exporting medicines to the US, the first formal action by the government after the drug maker pleaded guilty to criminal misconduct in that country. The office of the Drug Controller General of India (DCGI) will inspect Ranbaxy’s plants at Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh.

Ranbaxy Laboratories’ troubles began since it pleaded guilty to felony charges in the US related to manufacturing at two of its plants. The company on May 13 agreed to pay $500 million to settle civil and criminal charges of making fraudulent statements to the US Food and Drug Administration (USFDA) and selling adulterated drugs.

Peers
Company Name CMP
Sun Pharma Inds. 1837.15
Dr. Reddys Lab 1271.55
Cipla 1353.85
Zydus Lifesciences 1070.90
Lupin 2351.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: